A New Method of Complex Treatment of Patients with Malignant Cerebral Gliomas: Adjuvant Chemotherapy on Autologous Media Using Melatonin
The objective of the investigation is to study the survival rate of patients with malignant gliomas using adjuvant chemotherapy on autologous media using melatonin.
Materials and Methods. There has been studied a number of clinical factors in 291 patients with malignant cerebral gliomas who underwent complex therapy. The patients of the main group were divided into three subgroups according to treatment type: an operation and autohemochemotherapy, an operation and autohemochemotherapy with melatonin (Melaxen), and intraarterial chemotherapy with Melaxen.
Results. The analysis of general and uneventful survival rate according to Kaplan—Mayer over the more than 5 years’ period in all the patients under study has showed that general survival rate was higher in patients with adjuvant chemotherapy on automedia supported by Melaxen.
